2024
P22: Comparative Analysis of Efficacy of Intravenous Ketamine and Intranasal Esketamine in Treatment-Resistant Depression across Age Groups
Hutchison C, Hermida A, Keshishyan A, Kitay B, Chatham A, Hershenberg R, Posse P, Posse P. P22: Comparative Analysis of Efficacy of Intravenous Ketamine and Intranasal Esketamine in Treatment-Resistant Depression across Age Groups. International Psychogeriatrics 2024, 36: 130-131. DOI: 10.1017/s1041610224002552.Peer-Reviewed Original ResearchBeck Depression InventoryIntravenous ketamineIntranasal esketamineTreatment-resistant depressionRetrospective chart reviewAge groupsResistant depressionClinical responseDepression InventorySymptomatic improvementTreatment resistanceChart reviewEsketamineAcute coursePatientsDepressionKetamineTRDAgeBeckIntranasalInfusionGroupInventoryLifetime history of childhood adversity and substance abuse in patients with treatment resistant depression
Giampetruzzi E, McDonald W, Rice H, Kitay B, Hermida A, Posse P, Hershenberg R. Lifetime history of childhood adversity and substance abuse in patients with treatment resistant depression. Personalized Medicine In Psychiatry 2024, 43: 100122. DOI: 10.1016/j.pmip.2024.100122.Peer-Reviewed Original ResearchTreatment-resistant depressionAdverse childhood experiencesHistory of substance abuseSubstance abuseDepressive disorderAssociated with treatment-resistant depressionTreatment-resistant depressed patientsPersistent depressive disorderLifetime substance abuseEffects of adverse childhood experiencesRisk of substance abuseAssociation of adverse childhood experiencesACE subtypesACE exposureResistant depressionLifetime historyChildhood adversityChildhood experiencesAbuseClinical samplesDepressionDisordersLogistic regression analysisMDDSubstances
2023
P1: Dosing and treatment outcomes of rTMS for treatment-resistant depressed older adults in a naturalistic outpatient clinic population.
Tan A, Patricia A, Hershenberg R, Chatham A, Giampetruzzi E, Tsygankova V, Job G, Crowell A, Posse P, McDonald W, Kitay B. P1: Dosing and treatment outcomes of rTMS for treatment-resistant depressed older adults in a naturalistic outpatient clinic population. International Psychogeriatrics 2023, 35: 191-192. DOI: 10.1017/s1041610223003368.Peer-Reviewed Original ResearchRepetitive transcranial magnetic stimulationTreatment-resistant depressionWithin-group reductionsAnxiety scoresAnxiety symptom severityGroup 2Repetitive transcranial magnetic stimulation studiesGroup 1Depressed older adultsCognitive side effectsSelf-reported depressionEffects of repetitive transcranial magnetic stimulationReduction of depressionOlder adultsReduction of anxietyInternational meta-analysesAdult patientsRetrospective chart review of patientsChart review of patientsOutpatient sampleAnxiety symptomsResponse rateTranscranial magnetic stimulationDepressive symptomsNon-older patients